PMID- 35295757
OWN - NLM
STAT- MEDLINE
DCOM- 20220406
LR  - 20220406
IS  - 2235-2988 (Electronic)
IS  - 2235-2988 (Linking)
VI  - 12
DP  - 2022
TI  - Efficacy of Fecal Microbiota Transplantation in Irritable Bowel Syndrome: A 
      Meta-Analysis of Randomized Controlled Trials.
PG  - 827395
LID - 10.3389/fcimb.2022.827395 [doi]
LID - 827395
AB  - BACKGROUND: Randomized controlled trials (RCTs) have examined the efficacy of 
      fecal microbiota transplantation (FMT) in irritable bowel syndrome (IBS) with 
      inconsistent results. We performed a meta-analysis to assess both the short- and 
      long-term efficacy of FMT in IBS. METHODS: MEDLINE, EMBASE, and the Cochrane 
      Central Register were searched through September 2021. RCTs recruiting adult 
      patients with IBS that compared FMT with placebo with dichotomous data of 
      response to therapy were eligible. Dichotomous data were pooled to obtain a 
      relative risk (RR) of symptom not improving after therapy. RR was also pooled for 
      adverse events (AEs). Continuous data were calculated using a mean difference for 
      IBS-Quality of Life (IBS-QoL). GRADE methodology was used to assess quality of 
      evidence. RESULTS: The search strategy generated 658 citations. Seven RCTs 
      comprising 472 patients with IBS were included. FMT was not associated with a 
      significant improvement in global symptom in IBS at 12 weeks in comparison with 
      placebo (RR 0.75, 95% CI 0.43-1.31) with high heterogeneity between studies (I(2) 
      87%). Subgroup analyses showed that FMT was superior to placebo when administered 
      via colonoscopy or gastroscope (RR 0.70, 95% CI 0.51-0.96; RR 0.37, 95% CI 
      0.14-0.99, respectively, while FMT was inferior to placebo when administered via 
      oral capsules (RR 1.88, 95% CI 1.06-3.35). FMT induced a significant improvement 
      in IBS-QoL compared to placebo (mean difference 9.39, 95% CI 3.86-14.91) at 12 
      weeks. No significant difference in the total number of AEs was observed between 
      FMT and placebo (RR 1.20, 95% CI 0.59-2.47). FMT did not significantly improve 
      global symptom in IBS at 1-year follow-up compared with placebo (RR 0.90, 95% CI 
      0.72-1.12). The GRADE quality evidence to support recommending FMT in IBS was 
      very low. CONCLUSION: IBS patients may benefit from FMT when administered via 
      colonoscopy or gastroscope. FMT may improve the quality of life of IBS. The 
      long-term use of FMT in IBS warrants further investigation. There is 
      very-low-quality evidence to support recommending FMT in IBS.
CI  - Copyright (c) 2022 Wu, Lv and Wang.
FAU - Wu, Jie
AU  - Wu J
AD  - Department of Gastroenterology, The Second Xiangya Hospital of Central South 
      University, Changsha, China.
FAU - Lv, Liang
AU  - Lv L
AD  - Department of Gastroenterology, The Second Xiangya Hospital of Central South 
      University, Changsha, China.
FAU - Wang, Chunlian
AU  - Wang C
AD  - Department of Gastroenterology, The Second Xiangya Hospital of Central South 
      University, Changsha, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20220228
PL  - Switzerland
TA  - Front Cell Infect Microbiol
JT  - Frontiers in cellular and infection microbiology
JID - 101585359
SB  - IM
MH  - Adult
MH  - Colonoscopy
MH  - Fecal Microbiota Transplantation/adverse effects/methods
MH  - Humans
MH  - *Irritable Bowel Syndrome/therapy
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - Treatment Outcome
PMC - PMC8919053
OTO - NOTNLM
OT  - fecal microbiota transplantation
OT  - intestinal microbiota
OT  - irritable bowel syndrome
OT  - meta-analysis
OT  - microbiota
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/03/18 06:00
MHDA- 2022/04/07 06:00
PMCR- 2022/01/01
CRDT- 2022/03/17 05:13
PHST- 2021/12/15 00:00 [received]
PHST- 2022/02/07 00:00 [accepted]
PHST- 2022/03/17 05:13 [entrez]
PHST- 2022/03/18 06:00 [pubmed]
PHST- 2022/04/07 06:00 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fcimb.2022.827395 [doi]
PST - epublish
SO  - Front Cell Infect Microbiol. 2022 Feb 28;12:827395. doi: 
      10.3389/fcimb.2022.827395. eCollection 2022.